Par Drugs and Chemicals Limited (NSE:PAR)
89.31
+0.22 (0.25%)
Jun 1, 2026, 3:08 PM IST
Par Drugs and Chemicals Revenue
In the fiscal year ending March 31, 2026, Par Drugs and Chemicals had annual revenue of 1.08B INR with 6.62% growth. Par Drugs and Chemicals had revenue of 199.69M in the quarter ending March 31, 2026, a decrease of -10.57%.
Revenue
1.08B
Revenue Growth
+6.62%
P/S Ratio
1.02
Revenue / Employee
8.90M
Employees
121
Market Cap
1.10B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 1.08B | 66.83M | 6.62% |
| Mar 31, 2025 | 1.01B | 53.33M | 5.58% |
| Mar 31, 2024 | 956.40M | -1.08M | -0.11% |
| Mar 31, 2023 | 957.49M | 206.74M | 27.54% |
| Mar 31, 2022 | 750.74M | 143.23M | 23.58% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Ind-Swift Laboratories | 6.88B |
| Sigachi Industries | 4.86B |
| Balaxi Pharmaceuticals | 2.73B |
| Valiant Laboratories | 2.37B |
| Bafna Pharmaceuticals | 1.55B |
| Alpa Laboratories | 1.22B |
| Vaishali Pharma | 1.14B |
| Vivimed Labs | 883.92M |